Association of CBC-derived systemic inflammation markers with first-episode peritonitis in peritoneal dialysis.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-10-01 DOI:10.1080/17520363.2026.2740175

Fang Gao, Lulu Fan, Hongyu Xiang, Rui Zhang, Yangyan Luo

{"title":"Association of CBC-derived systemic inflammation markers with first-episode peritonitis in peritoneal dialysis.","authors":"Fang Gao, Lulu Fan, Hongyu Xiang, Rui Zhang, Yangyan Luo","doi":"10.1080/17520363.2026.2740175","DOIUrl":null,"url":null,"abstract":"Background: Peritoneal dialysis-associated peritonitis (PDAP) remains a major cause of technique failure in peritoneal dialysis (PD) patients. Novel complete blood count-derived inflammatory markers, including the systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate index of systemic inflammation (AISI), may provide accessible tools for early PDAP risk prediction.Methods: In this retrospective cohort study, 302 PD patients were stratified according to incident PDAP during follow-up. Restricted cubic splines assessed nonlinear associations. Multivariable logistic regression evaluated independent associations with first-episode PDAP. Receiver operating characteristic curves assessed predictive performance.Results: Baseline SII, SIRI, and AISI levels were significantly higher in the PDAP group than in the non-PDAP group (all p < 0.05). Higher Ln-SII (OR: 3.598; 95% CI: 2.204-5.872), Ln-SIRI (OR: 2.425; 95% CI: 1.584-3.714), and Ln-AISI (OR: 2.007; 95% CI: 1.403-2.871) were independently associated with increased PDAP risk (all p < 0.001). SII showed the highest discriminatory performance among the three markers, with an area under the curve of 0.689. A combined model incorporating SII, SIRI, and AISI achieved an AUC of 0.715.Conclusion: Higher SII, SIRI, and AISI levels were associated with an increased risk of first-episode PDAP. A combined model demonstrates promising predictive accuracy.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.1000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2740175","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Peritoneal dialysis-associated peritonitis (PDAP) remains a major cause of technique failure in peritoneal dialysis (PD) patients. Novel complete blood count-derived inflammatory markers, including the systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate index of systemic inflammation (AISI), may provide accessible tools for early PDAP risk prediction.

Methods: In this retrospective cohort study, 302 PD patients were stratified according to incident PDAP during follow-up. Restricted cubic splines assessed nonlinear associations. Multivariable logistic regression evaluated independent associations with first-episode PDAP. Receiver operating characteristic curves assessed predictive performance.

Results: Baseline SII, SIRI, and AISI levels were significantly higher in the PDAP group than in the non-PDAP group (all p < 0.05). Higher Ln-SII (OR: 3.598; 95% CI: 2.204-5.872), Ln-SIRI (OR: 2.425; 95% CI: 1.584-3.714), and Ln-AISI (OR: 2.007; 95% CI: 1.403-2.871) were independently associated with increased PDAP risk (all p < 0.001). SII showed the highest discriminatory performance among the three markers, with an area under the curve of 0.689. A combined model incorporating SII, SIRI, and AISI achieved an AUC of 0.715.

Conclusion: Higher SII, SIRI, and AISI levels were associated with an increased risk of first-episode PDAP. A combined model demonstrates promising predictive accuracy.

查看原文本刊更多论文

cbc来源的全身性炎症标志物与腹膜透析患者首发腹膜炎的相关性

背景：腹膜透析相关性腹膜炎（PDAP）仍然是腹膜透析（PD）患者技术失败的主要原因。新的全血细胞计数衍生炎症标志物，包括全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）和全身炎症总指数（AISI），可能为早期PDAP风险预测提供方便的工具。方法：对302例PD患者进行回顾性队列研究，根据随访期间PDAP的发生率进行分层。限制三次样条评估非线性关联。多变量逻辑回归评估与首发PDAP的独立关联。受试者工作特性曲线评估预测性能。结果：PDAP组的SII、SIRI和AISI基线水平显著高于非PDAP组（均p）。结论：SII、SIRI和AISI水平升高与首发PDAP风险增加相关。一个组合模型显示了有希望的预测准确性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.